BCAL Diagnostics Limited (ASX:BDX)

Australia · Delayed Price · Currency is AUD

0.0940

+0.0010 (1.08%)

Oct 7, 2026, 2:10 PM AEST

Market Cap	34.66M +33.4%
Revenue (ttm)	2.35M -11.2%
Net Income	-7.37M
EPS	-0.02
Shares Out	368.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,194
Open	0.0940
Previous Close	0.0930
Day's Range	0.0900 - 0.0940
52-Week Range	0.0520 - 0.1550
Beta	0.74
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 17, 2026

About BCAL Diagnostics

BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 and is headquartered in Sydney, Australia. [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2010

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol BDX

Full Company Profile

Financial Performance

In fiscal year 2026, BCAL Diagnostics's revenue was 2.35 million, a decrease of -11.25% compared to the previous year's 2.65 million. Losses were -7.37 million, 1.80% more than in 2025.

Financial Statements